What a congressional investigation reveals about FDA s approval of Aduhelm advisory.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from advisory.com Daily Mail and Mail on Sunday newspapers.
The biotechnology company Biogen and its regulator, the Food and Drug Administration, worked in concert ignoring internal concerns from the company and skirting the agency s own written guidance to allow the Alzheimer s treatment Aduhelm to receive accelerated approval and hit the market at a cost to patients of $56,000 annually, according to a report released Thursday by two House committees.
Novo Nordisk has spoken out in support of Victoza after influential US consumer group Public Citizen called for the diabetes drug to be withdrawn. - News - PharmaTimes